Molecule Name
27T51
A Powerful Research and Development Engine
Explore Regeneron’s clinical pipeline
Our pipeline is powered by end-to-end research and development capabilities, and our portfolio of investigational medicines reflects the true collaborative spirit of Regeneron. The Research team discovers promising new drug candidates. From there, the Global Development team brings these investigational medicines through the full clinical development process.
This chart displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authority for the indications described in this section.
Download our corporate fact sheet
Displaying 0 items
Select Phase(s)
Select Therapeutic Area(s)
Select Modality(s)
Biologics
Genetic Medicines
Cell Medicines
Molecule Name
Therapeutic Area(s)
Modality
Indication
Target
Therapeutic Area(s)
Oncology
Modality
Cell therapy
Indication
Ovarian cancer
Target
MUC16
Molecule Name
ALN-F1202
In collaboration with Alnylam
Therapeutic Area(s)
Hematology
Modality
Gene silencing
Indication
Healthy volunteers
Target
Factor XII
Molecule Name
ALN-HTT02
In collaboration with Alnylam
Therapeutic Area(s)
Neurology
Modality
Gene silencing
Indication
Huntington’s disease
Target
HTT
Molecule Name
ALN-SOD*
In collaboration with Alnylam
*on U.S. FDA clinical hold;
enrolling ex-U.S.
Therapeutic Area(s)
Neurology
Modality
Gene silencing
Indication
SOD1 amyotrophic lateral sclerosis (ALS)
Target
SOD1
Molecule Name
DUPILUMAB/LINVOSELTAMAB
Therapeutic Area(s)
Immunology & Inflammation
Modality
Bispecific antibodies, Monoclonal antibodies
Indication
Severe food allergy
Target
IL-4R/BCMA and CD3
Molecule Name
LINVOSELTAMAB
Therapeutic Area(s)
Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma
Target
BCMA and CD3
Molecule Name
NEZASTOMIG (REGN5678)
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Renal cell carcinoma
Target
PSMA and CD28
Molecule Name
NEZASTOMIG (REGN5678) / REGN4336
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Prostate cancer
Target
PSMA and CD28 / PSMA and CD3 combo
Molecule Name
ODRONEXTAMAB
Therapeutic Area(s)
Oncology, Hematology
Modality
Bispecific antibodies
Indication
Certain B-cell malignancies
Target
CD20 and CD3
Molecule Name
REGN10597
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Solid tumors (Phase 1/2)
Target
PD1-IL2Ra
Molecule Name
REGN4336
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Prostate cancer
Target
PSMA and CD3
Molecule Name
REGN7945
Therapeutic Area(s)
Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma
Target
CD38 and CD28
Molecule Name
VONSETAMIG (REGN5459)
Therapeutic Area(s)
Oncology, Hematology
Modality
Bispecific antibodies
Indication
Transplant desensitization in patients with chronic kidney disease
Target
BCMA and CD3
Molecule Name
REGN5668
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Platinum-resistant ovarian cancer
Target
MUC16 and CD28
Molecule Name
REGN5837
Therapeutic Area(s)
Hematology
Modality
Bispecific antibodies
Indication
B-NHL
Target
CD22 and CD28
Molecule Name
REGN9533
Therapeutic Area(s)
Hematology
Modality
Monoclonal antibodies
Indication
Healthy volunteers
Target
Factor XII
Molecule Name
REGV131-LNP1265
Therapeutic Area(s)
Hematology
Modality
Gene editing
Indication
Hemophilia B
Target
Factor 9
Molecule Name
Therapeutic Area(s)
Modality
Indication
Target
Molecule Name
CEMIPLIMAB
Therapeutic Area(s)
Oncology
Modality
Monoclonal antibodies
Indication
Neoadjuvant cutaneous squamous cell carcinoma (CSCC); First-line non-small cell lung cancer (NSCLC), BNT116 combination; Neoadjuvant NSCLC; Neoadjuvant hepatocellular carcinoma (HCC)
Target
PD-1
Molecule Name
DAVUTAMIG (REGN5093)
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
MET-altered advanced NSCLC
Target
Two distinct MET epitopes
Molecule Name
DB-OTO
Therapeutic Area(s)
Rare Disease
Modality
Gene therapy
Indication
Hearing deficit due to variants of the otoferlin gene (Phase 1/2)
Target
AAV-based gene therapy
Molecule Name
DUPILUMAB
In collaboration with Sanofi
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Ulcerative colitis
Target
IL-4R alpha subunit
Molecule Name
FIANLIMAB
Therapeutic Area(s)
Oncology
Modality
Monoclonal antibodies
Indication
First-line advanced non-small cell lung cancer (NSCLC) (Phase 2/3); Perioperative NSCLC; Perioperative melanoma
Target
LAG-3
Molecule Name
ITEPEKIMAB
In collaboration with Sanofi
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Non-cystic fibrosis bronchiectasis (NCFB); Chronic rhinosinusitis without nasal polyposis (CRSsNP)
Target
IL-33
Molecule Name
LINVOSELTAMAB
Therapeutic Area(s)
Oncology, Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma (pivotal study); Earlier (pre-malignant) multiple myeloma; Monoclonal gammopathy of undetermined significance (MGUS); Light chain amyloidosis (ALA) (Phase 1/2)
Target
BCMA and CD3
Molecule Name
NEZASTOMIG (REGN5678)
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Prostate cancer
Target
PSMA and CD28
Molecule Name
RAPIROSIRAN (ALN-HSD)
Therapeutic Area(s)
Immunology & Inflammation
Modality
Gene silencing
Indication
Metabolic dysfunction-associated steatohepatitis (MASH)
Target
HSD17B13
Molecule Name
REGN7075
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Solid tumors
Target
EGFR and CD28
Molecule Name
REGN7257
Therapeutic Area(s)
Hematology
Modality
Monoclonal antibodies
Indication
Aplastic anemia
Target
IL2Rg
Molecule Name
REGN7508
Therapeutic Area(s)
Hematology
Modality
Monoclonal antibodies
Indication
Thrombosis
Target
Factor XI
Molecule Name
REGN7999
Therapeutic Area(s)
Hematology
Modality
Monoclonal antibodies
Indication
Iron overload in beta-thalassemia
Target
TMPRSS6
Molecule Name
REGN9933
Therapeutic Area(s)
Hematology
Modality
Monoclonal antibodies
Indication
Thrombosis
Target
Factor XI
Molecule Name
SARILUMAB
In collaboration with Sanofi
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Systemic juvenile idiopathic arthritis (sJIA) (pivotal study)
Target
IL-6R
Molecule Name
UBAMATAMAB (REGN4018)
Therapeutic Area(s)
Oncology
Modality
Bispecific antibodies
Indication
Platinum-resistant ovarian cancer
Target
MUC16 and CD3
Molecule Name
Therapeutic Area(s)
Modality
Indication
Target
Molecule Name
CEMIPLIMAB
Therapeutic Area(s)
Oncology
Modality
Monoclonal antibodies
Indication
Adjuvant cutaneous squamous cell carcinoma (CSCC); Early-stage CSCC (intralesional)
Target
PD-1
Molecule Name
DUPILUMAB
In collaboration with Sanofi
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Asthma in pediatrics (2–5 years of age); bullous pemphigoid; chronic spontaneous urticaria (CSU); chronic pruritis of unknown origin (CPUO); Lichen simplex chronicus
Target
IL-4R alpha subunit
Molecule Name
EYLEA HD (AFLIBERCEPT) 8 MG
In collaboration with Bayer
Therapeutic Area(s)
Ophthalmology
Modality
Traps
Indication
Retinal vein occlusion (RVO)
Target
VEGF
Molecule Name
FIANLIMAB
Therapeutic Area(s)
Oncology
Modality
Monoclonal antibodies
Indication
First-line metastatic melanoma; Adjuvant melanoma
Target
LAG-3
Molecule Name
GARETOSMAB
Therapeutic Area(s)
Rare Disease
Modality
Monoclonal antibodies
Indication
Fibrodysplasia ossificans progressiva (FOP)
Target
Activin A
Molecule Name
ITEPEKIMAB
In collaboration with Sanofi
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Chronic obstructive pulmonary disease (COPD); Chronic rhinosinusitis without nasal polyposis (CRSsNP)
Target
IL-33
Molecule Name
LINVOSELTAMAB
Therapeutic Area(s)
Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma
Target
BCMA and CD3
Molecule Name
ODRONEXTAMAB
Therapeutic Area(s)
Hematology
Modality
Bispecific antibodies
Indication
Follicular lymphoma (FL); Diffuse large B-cell lymphoma (DLBCL)
Target
CD20 and CD3
Molecule Name
POZELIMAB (REGN3918)
Therapeutic Area(s)
Ophthalmology, Neurology, Hematology
Modality
Gene silencing, Monoclonal antibodies
Indication
Myasthenia gravis, cemdisiran combination; paroxysmal nocturnal hemoglobinuria (PNH), cemdisiran combination; Geographic atrophy, cemdisiran combination
Target
C5
Molecule Name
REGN1908-1909
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Cat allergy
Target
Multi antibody therapy to Fel d 1
Molecule Name
REGN5713-5715
Therapeutic Area(s)
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Birch allergy
Target
Bet v 1
Pipeline last updated: April 30, 2025
Technology for now and the future
Technology is foundational to our work inventing new medicines. By combining the deep scientific expertise of our team with our proprietary VelociSuite® technologies, as well as other cutting-edge technologies, we accelerate the way medicines are traditionally discovered and developed.
Explore our technology
Explore our clinical trials
The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. If you are in the U.S., learn more about our clinical trials or find a relevant one near you.
Find trials